Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation approach aims to stop pancreatic cancer return after surgery

NCT ID NCT05043857

Disease control Sponsor: Istituto Clinico Humanitas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a precise, high-dose radiation technique called SBRT can lower the chance of cancer coming back in the pancreas area after surgery. The study involves 50 adults with pancreatic cancer who had surgery and are at high risk of recurrence. They will receive SBRT in 5 sessions, targeting the surgical bed and nearby areas.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Stereotactic Body Radiotherapy (SBRT)
What this could lead to
If successful, this could offer a more effective and shorter radiation option after surgery to help prevent the cancer from coming back in the pancreas area.
What could go wrong
This is a small, early-phase trial (50 people) without a comparison group, so results may not be definitive. Radiation can also cause side effects to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2021

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Surgically treated T1-T4 adenocarcinoma with or without prior chemotherapy AND close (\<2.5mm)/positive resection margin AND/OR N1 staging at lymphadenectomy * ECOG performance status \<2 * Age \> 18 * Estimated life expectancy \> 6 months * Ability to provide written informed consent * Cardiovascular comorbidities limiting life expectancy Exclusion Criteria: * Metastatic disease * Biliary tract or neuroendocrine neuroplasm * History of malignancies except for non-melanoma cutaneous tumors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreas cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreas cancer

Contacts and locations

Locations

  • Humanitas Research Hospital

    Rozzano, MI, 20089, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.